The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma.
 
Glenn J. Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
Liam B Oakley
No Relationships to Disclose
 
Ruichao Shi
No Relationships to Disclose
 
Anne ONeill
No Relationships to Disclose
 
Kee-Young Shin
No Relationships to Disclose
 
Kartik Sehgal
Honoraria - AmerisourceBergen; Binacea; Medscape; Pri-Med
Consulting or Advisory Role - Equinox Group; Exelixis; Guidepoint Global; Medscape; Scholar Rock
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Binacea; Merck; Pri-Med
 
Michael J. Dennis
Consulting or Advisory Role - MJH Life Sciences
 
Vickie Y. Jo
No Relationships to Disclose
 
Kristine S. Wong
No Relationships to Disclose
 
Robert I. Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Coherus Biosciences; Eisai; EMD Serono; Galera Therapeutics; Genmab; GlaxoSmithKline; Merck; Merus; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix